LIVERFASt™
Staging of Liver Fibrosis, Activity, and Steatosis in MASLD/MASH
CommercialActive
Key Facts
Indication
Staging of Liver Fibrosis, Activity, and Steatosis in MASLD/MASH
Phase
Commercial
Status
Active
Company
About Fibronostics
Fibronostics is a commercial-stage diagnostics company providing AI-powered, blood-based tests for metabolic liver disease. Its core technology, LIVERFASt™, analyzes 10 common biomarkers and patient data to generate a score that correlates with biopsy results for fibrosis, inflammation, and fat content. The company operates a CAP/CLIA certified lab, targets physicians, health systems, and pharma companies, and positions its test as a superior, non-invasive alternative to tools like FIB-4 and FibroScan. Founded in 2015 and headquartered in New Orleans, it is a private company in the early revenue stage.
View full company profile